Early Dietary Intervention with a Mixture of Prebiotic Oligosaccharides Reduces the Incidence of Allergic Manifestations and Infections during the first two Years of Life

Center for Infant Nutrition, Macedonio Melloni Hospital, University of Milan, Milan 20129, Italy.
Journal of Nutrition (Impact Factor: 3.88). 06/2008; 138(6):1091-5.
Source: PubMed


A mixture of neutral short-chain galactooligosaccharides (scGOS) and long-chain fructooligosaccharides (lcFOS) has been shown to reduce the incidence of atopic dermatitis (AD) and infectious episodes during the first 6 mo of life. This dual protection occurred through the intervention period. The present study evaluated if these protective effects were lasting beyond the intervention period. In a prospective, randomized, double-blind, placebo-controlled design, healthy term infants with a parental history of atopy were fed either a prebiotic-supplemented (8 g/L scGOS/lcFOS) or placebo-supplemented (8 g/L maltodextrin) hypoallergenic formula during the first 6 mo of life. Following this intervention period, blind follow-up continued until 2 y of life. Primary endpoints were cumulative incidence of allergic manifestations. Secondary endpoints were number of infectious episodes and growth. Of 152 participants, 134 infants (68 in placebo, 66 in intervention group) completed the follow-up. During this period, infants in the scGOS/lcFOS group had significantly lower incidence of allergic manifestations. Cumulative incidences for AD, recurrent wheezing, and allergic urticaria were higher in the placebo group, (27.9, 20.6, and 10.3%, respectively) than in the intervention group (13.6, 7.6, and 1.5%) (P < 0.05). Infants in the scGOS/lcFOS group had fewer episodes of physician-diagnosed overall and upper respiratory tract infections (P < 0.01), fever episodes (P < 0.00001), and fewer antibiotic prescriptions (P < 0.05). Growth was normal and similar in both groups. Early dietary intervention with oligosaccharide prebiotics has a protective effect against both allergic manifestations and infections. The observed dual protection lasting beyond the intervention period suggests that an immune modulating effect through the intestinal flora modification may be the principal mechanism of action.

Download full-text


Available from: Sertac Arslanoglu
    • "In addition, synbiotics – where this species and GOS act synergistically – have been used in different clinical studies proving their beneficial effect on health (Martinez et al., 2011; Prasad et al., 2013) et al., 2002). In addition to their impact on gut bacterial taxa, prebiotics have been shown to enhance host health by directly inhibiting adherence of pathogens to the host epithelial cell surface (Kunz et al., 2000) and modulating the colon microenvironment, which results in a reduction of intestinal infections (Arslanoglu et al., 2008; Shoaf et al., 2006). The role of Helicobacter in gastric cancer is well-documented (Plummer et al., 2014; Polk and Peek, 2010) and recent reports suggest a potential role of this bacterium in IBD (Hansen, 2009; Laharie et al., 2009; Whary et al., 2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Prebiotics are selectively fermented ingredients that result in specific changes in the composition and/or activity of the gastrointestinal microbiota, thus conferring benefit(s) upon the host health. The aim of this study was to evaluate the influence of a β(1-4)galacto-oligosaccharides (GOS) formulation consisting of 90% pure GOS (GOS90), on the composition and activity of the mouse gut microbiota. Germ-free mice were colonised with microbiota from four pathogen-free wt 129 mice donors (SPF), and stools were collected during a feeding trial in which GOS90 was delivered orally for 14 days. Pyrosequencing of 16S rDNA amplicons showed that Bifidobacterium and specific Lactobacillus, Bacteroides and Clostridiales were more prevalent in GOS90-fed mice after 14 days, although the prebiotic impact on Bifidobacterium varied among individual mice. Prebiotic feeding also resulted in decreased abundance of Bacteroidales, Helicobacter and Clostridium. High-throughput quantitative PCR showed an increased abundance of Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, Bifidobacterium lactis and Bifidobacterium gallicum in the prebiotic-fed mice. Control female mice showed a higher diversity (phylogenetic diversity (PD) = 15.1±3.4 in stools and PD = 13.0±0.6 in intestinal contents) than control males (PD = 7.8±1.6 in stool samples and PD = 9.5±1.0 in intestinal contents). GOS90 did not modify inflammatory biomarkers (interleukin (IL)-6, IL-12, IL-1β, interferon gamma and tumour necrosis factor alpha). Decreased butyrate, acetate and lactate concentrations in stools of prebiotic fed mice suggested an increase in colonic absorption and reduced excretion. Overall, our results demonstrate that GOS90 is capable of modulating the intestinal microbiome resulting in expansion of the probiome (autochtonous commensal intestinal bacteria considered to have a beneficial influence on health).
    No preview · Article · Feb 2016 · Beneficial Microbes
  • Source
    • "Galactooligosaccharides (GOS) and lactulose are recognised as prebiotic carbohydrates and they are widely used in Japan, Europe and the United States (Tuohy et al. 2005). GOS are usually produced by transgalactosylation of lactose using microbial β-galactosidases, and in addition to their prebiotic character, other health benefits such as improvement of mineral absorption, prevention of intestinal infections and enhancement of immune function among others have been described (Pérez-Conesa et al. 2006; Arslanoglu et al. 2008; Vulevic et al. 2008; Ebersbach et al. 2010). Lactulose, a synthetic disaccharide manufactured by lactose isomerisation in basic media, was the first carbohydrate commercialised with recognised beneficial effects on gut bifidobacteria (Méndez & Olano, 1979; Rycroft et al. 2001). "
    [Show abstract] [Hide abstract]
    ABSTRACT: β-Galactosidases from Kluyveromyces lactis and Kluyveromyces marxianus isolated from artisanal ewes’ milk cheeses, were used to transgalactosylate lactose from cheese whey permeate (WP). The content of galactooligosaccharides (GOS) obtained by transgalactosylation was comparable with that formed using pure lactose as substrate. In order to obtain a mixture with higher prebiotic oligosaccharide content, isomerisation of the transgalactosylated WP was carried out using sodium aluminate as catalyst. The transgalactosylated mixtures at 6 h of reaction contained amounts of prebiotic carbohydrates (tagatose, lactulose, GOS and oligosaccharides derived from lactulose, OsLu) close to 50 g/100 g of total carbohydrates for all the strains tested, corresponding to 322 g prebiotics/kg whey permeate. Thus, the suitability of this methodology to produce mixtures of dietary non-digestible carbohydrates with prebiotic properties from WP has been demonstrated, which is interesting for the food industry since it increases the value and the applicability of this by-product from cheese manufacture.
    Full-text · Article · May 2015 · Journal of Dairy Research
  • Source
    • "Upper limit Z-value p-value Arslanoglu et al., 2008 Moro et al., 2006 Passeron et al., 2006 Wu et al., 2012 "
    [Show abstract] [Hide abstract]
    ABSTRACT: The incidence of allergic diseases has increased in recent decades. Therefore, the aim of this systematic review was to assess the efficacy of prebiotics for the prevention and treatment of allergic manifestations in children. We sought to conduct a systematic review of the effectiveness of prebiotics in the prevention and treatment of allergic diseases in children. We searched the MEDLINE, EMBASE, Cochrane Library, LILACS, SciELO, IBECS, Web of Science and Clinical Trials databases as well as Google Scholar and the references of the articles identified. Randomised clinical trials, in which one of the treatments was performed with prebiotics and the control group was treated with placebo, were included in the review. The data selection were performed by two reviewers, and the study quality was evaluated according to the Consolidated Standards of Reporting Trials (CONSORT) items, according to the recommendations for improving the quality of reports of randomised clinical trials. The selected studies showed heterogeneity with regard to the participants, albeit with similar outcomes. The treatment group size ranged from 134 to 259 children, and the studies compared prebiotic to placebo treatment in each group. In general, these articles showed a trend toward less allergic reactions in the groups receiving active therapy with prebiotics. Although there was a trend for reduced allergic symptoms following the administration of prebiotics, there was not sufficient evidence to establish that such treatment is effective for the prevention of allergies in children.
    Full-text · Article · Oct 2013
Show more